LobbyingAuravax Therapeutics lobbying by quarter
Auravax Therapeutics's latest lobbying report covers Q1 2026, at under $5,000. The four quarters Q4 2025–Q3 2026 total $50K. Its first report covers Q1 2025; the issues it reports most are Budget/Appropriations and Defense.
Auravax Therapeutics
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $50K
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q1 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q1 2025 | $0 | 1 |
| Q2 2025 | $0 | 1 |
| Q3 2025 | $0 | 1 |
| Q4 2025 | $50K | 1 |
| Q1 2026 | $0 | 1 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Budget and appropriations$16.7K · 4 reports
- Defense$16.7K · 4 reports
- Health issues$16.7K · 4 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- SENATE4 reports
Firms it paid
| Firm | ||
|---|---|---|
| McAllister & Quinn | $50K | 5 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| ANDREW QUINN | SA, LA - Rep. Hoyer | Q4 2025 |
| BRANDON REA | LI - Rep. Cuellar | Q4 2025 |
| ELIZABETH FOLEY | LA - Rep. McCollum | Q4 2025 |
| WESTON HAYCOCK | SA, LA, PS - Sen. Tester | Q4 2025 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 04/20for Q1 | McAllister & Quinn | Under $5,000 |
| 01/20for Q4 2025 | McAllister & Quinn | $50K |
| 25/10/20for Q3 2025 | McAllister & Quinn | Under $5,000 |
| 25/10/20for Q2 2025 | McAllister & Quinn | Under $5,000 |
| 25/10/20for Q1 2025 | McAllister & Quinn | Under $5,000 |
| 25/10/14for Q1 2025 | McAllister & Quinn | Under $5,000 |